Current Report Filing (8-k)
February 14 2018 - 2:37PM
Edgar (US Regulatory)
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities
Exchange Act of 1934
Date of Report (Date of earliest event reported):
February 13, 2018
BIOANALYTICAL SYSTEMS, INC.
|
(Exact name of registrant as specified in its charter)
|
Indiana
|
|
0-23357
|
|
35-1345024
|
(State or other jurisdiction of incorporation or organization)
|
|
(Commission File Number)
|
|
(I.R.S. Employer Identification No.)
|
2701 KENT AVENUE
WEST LAFAYETTE, INDIANA
|
|
47906-1382
|
(Address of principal executive offices)
|
|
(Zip Code)
|
Registrant’s telephone number, including
area code: (765) 463-4527
Check the appropriate box below if the Form 8-K filing is intended
to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:
|
¨
|
Written communications pursuant to Rule 425 under the
Securities Act (17 CFR 230.425)
|
|
¨
|
Soliciting material pursuant to Rule 14a-12 under the
Exchange Act (17 CFR 240.14a-12)
|
|
¨
|
Pre-commencement communications pursuant to Rule 14d-2(b)
under the Exchange Act (17 CFR 240.14d-2(b))
|
|
¨
|
Pre-commencement communications pursuant to Rule 13e-4(c)
under the Exchange Act (17 CFR 240.13e-4(c))
|
Indicate by check mark whether the registrant
is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2
of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).
Emerging growth company
¨
If an emerging growth company, indicate
by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial
accounting standards provided pursuant to Section 13(a) of the Exchange Act.
¨
The information provided
in Item 2.02 and Item 9.01 of this Form 8-K is being furnished and shall not be deemed “filed” for the purpose of Section
18 of the Securities Exchange Act of 1934, as amended, or otherwise subject to the liabilities of that Section. The information
in Item 2.02 and Item 9.01 of this Form 8-K shall not be incorporated by reference into any registration statement or other document
pursuant to the Securities Act of 1933, as amended.
|
Item 2.02.
|
Results of Operations and Financial Condition.
|
On February 13, 2018,
Bioanalytical Systems, Inc. issued a press release announcing results for the first three months of fiscal 2018 ended December
31, 2017. The full text of the press release is furnished as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.
|
Item 9.01.
|
Financial Statements and Exhibits.
|
SIGNATURES
Pursuant to the requirements of the Securities
Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.
|
Bioanalytical Systems, Inc.
|
|
|
|
|
|
|
|
|
Date: February 14, 2018
|
By:
|
/s/ Jill C. Blumhoff
|
|
|
Jill C Blumhoff
|
|
|
Chief Financial Officer, Vice President of Finance
|
Exhibit Index
Bioanalytical Systems (NASDAQ:BASI)
Historical Stock Chart
From Apr 2024 to May 2024
Bioanalytical Systems (NASDAQ:BASI)
Historical Stock Chart
From May 2023 to May 2024